Drug
Azacitidine clinical trials
Also written Vidaza, U-18496, NSC-102816 and Onureg.
- studies test it
- 480
- open now
- 142
- in phase 3
- 37
- first study started
- 1999
Keep track of what changes. Save the Azacitidine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Azacitidine
- 329
- Azacytidine
- 108
- Ladakamycin
- 106
- 5-AZC
- 104
Development codes
- U-18496
- 74
Studies by the year they started
476 studies that test it; most in 2026 (43); 4 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 5 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 11 |
| 2006 | 13 |
| 2007 | 9 |
| 2008 | 15 |
| 2009 | 16 |
| 2010 | 25 |
| 2011 | 17 |
| 2012 | 14 |
| 2013 | 23 |
| 2014 | 12 |
| 2015 | 19 |
| 2016 | 13 |
| 2017 | 23 |
| 2018 | 20 |
| 2019 | 23 |
| 2020 | 30 |
| 2021 | 26 |
| 2022 | 25 |
| 2023 | 23 |
| 2024 | 36 |
| 2025 | 32 |
| 2026 | 43 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 220
- Phase 2
- 290
- Phase 3
- 37
- Phase 4
- 4
- No phase
- 21
What it is tested for
Each study’s main condition, where its own words name it.
- Leukemia
- 15
Who runs them
Industry 111 · Other 369
M.D. Anderson Cancer Center (58) · National Cancer Institute (NCI) (30) · The First Affiliated Hospital of Soochow University (16) · Celgene (13) · Institute of Hematology & Blood Diseases Hospital, China (11) · Groupe Francophone des Myelodysplasies (10) · AbbVie (10) · Washington University School of Medicine (7)
Often tested with
Tested in the same studies.
Venetoclax (129) · Cytarabine (43) · Decitabine (21) · Lenalidomide (18) · Tucidinostat (17) · Daunorubicin (13) · Gilteritinib (10) · Ivosidenib (9)
Studies
Open first, then newest update. How each study uses Azacitidine is read from its arms, and is right about nine times in ten.
Testing it · 480
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Azacitidine
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06177067Written as Azacitidine
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingPhase 1Roswell Park Cancer InstituteNCT07679334Written as Azacitidine
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Azacitidine
- Sonrotoclax Plus Azacitidine in Patients With MDS-IB2RecruitingPhase 1/2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07885397Written as Azacitidine (AZA)
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT07388563Written as azacitidine
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as Azacitidine
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07159620Written as Azacitidine (AZA)
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 MutationsRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07646821Written as Azacitidine (AZA)
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as Azacitidine (AZA)
- A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06616636Written as Azacitidine
- Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung CancerNot yet recruitingPhase 1/2Nob Hill Therapeutics, Inc.NCT07864584Written as NHT102
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07060001Written as Azacitidine (AZA)
- Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07862517Written as Azacitidine
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingPhase 2/3Taiho Oncology, Inc.NCT04256317Written as Azacitidine
- Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04140487Written as Azacitidine
- A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07392242Written as Azacitidine
- Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03586609Written as Azacitidine
- Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell TransplantationRecruitingPhase 1OHSU Knight Cancer InstituteNCT07548983Written as Azacitidine
- Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating AgentRecruitingPhase 2University of California, DavisNCT07304011Written as Azacitidine
See all 480 studies that test Azacitidine →
Given in every arm · 156 — Azacitidine is usual care beside what is tested
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)RecruitingPhase 2/3AbbVieNCT07581002Written as Azacitidine
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06317649Written as Azacitidine
- Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic SyndromesRecruitingPhase 2Faron Pharmaceuticals LtdNCT07672769Written as azacitidine
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).RecruitingPhase 3Ascentage Pharma Group Inc.NCT06641414Written as Azacitidine Injection
- Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AMLRecruitingPhase 2Beijing 302 HospitalNCT07078591Written as Azacitidine (AZA)
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingPhase 3PETHEMA FoundationNCT07478991Written as Azacitidine
- Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AMLRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07508982Written as Azacitidine
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT06763341Written as Azacitidine
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingPhase 3Janssen Research & Development, LLCNCT06852222Written as Azacitidine (AZA)
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Azacitidine
- A Study of BGB-11417 in Participants With Myeloid MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT04771130Written as Azacitidine
- A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaRecruitingPhase 1/2Therapeutic Advances in Childhood Leukemia ConsortiumNCT05849662Written as Azacitidine
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxRecruitingPhase 2Timothy PardeeNCT07471841Written as Azacitidine (AZA)
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)RecruitingPhase 1Kittika PoonsombudlertNCT07177079Written as Azacitidine
- A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07754799Written as Azacitidine
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)RecruitingPhase 3PedAL BCU, LLCNCT05183035Written as Azacitidine
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2BeOne MedicinesNCT07770698Written as Azacitidine
- Study of SA+X in the Treatment of Newly Diagnosed AMLRecruitingPhase 2Ruijin HospitalNCT07548710Written as Azacitidine (AZA)
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Azacitidine
- Study to Evaluate the Safety and Tolerability of EP0042RecruitingPhase 1/2Ellipses PharmaNCT04581512Written as Azacitidine (AZA)
Showing 20 of 156.
As the comparator · 16 — what is tested is compared with Azacitidine
- Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDSRecruitingPhase 1Stelexis BioSciencesNCT06533761Written as Azacitadine (AZA)
- Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPNRecruitingPhase 2Virginia Commonwealth UniversityNCT07710534Written as Azacitidine plus venetoclax (AZA+VEN)
- Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AMLNot yet recruitingPhase 3Ruijin HospitalNCT07735117Written as azacitidine
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT05586074Written as Azacitidine
- Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid LeukemiaRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT06532552Written as VA
- Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLCompletedPhase 2GWT-TUD GmbHNCT04061239Written as Azacitidine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Azacitidine
- A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationCompletedPhase 3Astellas Pharma Global Development, Inc.NCT02421939Written as Azacitidine
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as Azacitidine
- Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs VidazaCompletedPhase 1American Regent, Inc.NCT01290302Written as Vidaza®
- Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive ChemotherapyWithdrawnPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06770257Written as Azacitidine
- An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationCompletedPhase 3CelgeneNCT02577406Written as Azacitidine
- Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486CompletedPhase 2Kirby InstituteNCT03493646Written as Azacitidine
- Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid MalignancyStatus unknownPhase 4Shenzhen Second People's HospitalNCT03873311Written as Azacytidine
- A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid LeukemiaTerminatedPhase 1PfizerNCT02954653Written as Azacitidine
- Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic SyndromesStatus unknownPhase 2Assistance Publique - Hôpitaux de ParisNCT01342692Written as Azacitidine
Codes
What other systems call Azacitidine · ClinicalTrials.gg INT007036
- MeSH (NLM) D001374AzacitidineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M801H13NRUAZACITIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 1251Confirmed FDA, Wikidata
- Wikidata Q416451azacitidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C288AzacitidineOne source FDA
- DrugBank DB00928One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D001374 | Azacitidine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M801H13NRU | AZACITIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1251 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416451 | azacitidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C288 | Azacitidine | One source FDA |
| DrugBank | DB00928 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.